This is for $150 mn and will help it to expand its presence in its third-largest market. The portfolio will be transferred to Lupin on Dec. 31, subject to regulatory approvals and certain closing conditions. The acquisition, which will be done by Lupin’s Japanese generic drug unit Kyowa Pharmaceutical Industry Co Ltd, will give Lupin access to Japanese branded pharmaceutical market and strengthen its speciality business portfolio.

Lupin Ltd agrees to buy a portfolio of 21 drugs from Japan's Shionogi

Leave a Reply

Your email address will not be published. Required fields are marked *